Trial Profile
A Multicenter, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Alogliptin Compared to Glipizide in Elderly Subjects With Type 2 Diabetes.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Alogliptin (Primary) ; Glipizide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Sponsors Takeda Global Research and Development Center
- 05 Oct 2012 Results presented at the 48th Annual Meeting of the European Association for the Study of Diabetes.
- 24 Mar 2012 Planned number of patients 470 added as reported by European Clinical Trials Database.
- 08 Dec 2011 Primary endpoint 'Proportion-of-glycosylated-haemoglobin' has been met.